Frontline Immunotherapy Combo Setbacks Strike NSCLC – OncLive
OncLive |
Frontline Immunotherapy Combo Setbacks Strike NSCLC
OncLive Bristol-Myers Squibb (BMS) and AstraZeneca have each announced separate delays in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer (NSCLC), … |
RIABiz |
DOL rule will be undone, in a cruel twist, by the Department of Labor — essentially by a Trump order to cut red …
RIABiz Sources disagree semantically about whether the DOL, based on this development, is dead, delayed or in some sort of cryogenic suspended animation if what we’re hearing out of Washington is right. What is clear, if this Texas court angle is true, is … |
Invest Daily News: Market Research News by Market.Biz (press release) |
Successful Immunotherapy Requires System-Wide Immune Response
UCSF News Services New research led by researchers from UC San Francisco and Stanford University has found that successful cancer immunotherapy appears to depend on whether the treatment can trigger a system-wide immune response, rather than just a local response … Scrambled DNA inside tumours might hinder cancer immunotherapyCancer Research UK Cancer Immunotherapy Market will generate new growth …Medgadget (blog) Non-Specific Cancer Immunotherapy Drug Sales Industry – Market Outlook – Latest Development and Market TrendsSatellite PR News (press release) Science Daily –Invest Daily News: Market Research News by Market.Biz (press release) –Military Technologies all 12 news articles » |
GeekWire |
Could immunotherapy cure HIV? $2.6M grant will help Fred Hutch researcher find out
GeekWire Immunotherapy — using the body’s immune system to fight disease — has already made great strides in cancer treatment, with the Seattle region emerging as an epicenter for the approach. But could this technology also treat HIV, a disease that is … |